Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Operating Leases (2019 - 2025)

Historic Operating Leases for Serina Therapeutics (SER) over the last 5 years, with Q3 2025 value amounting to $311000.0.

  • Serina Therapeutics' Operating Leases fell 3889.98% to $311000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $311000.0, marking a year-over-year decrease of 3889.98%. This contributed to the annual value of $460000.0 for FY2024, which is 3185.19% down from last year.
  • According to the latest figures from Q3 2025, Serina Therapeutics' Operating Leases is $311000.0, which was down 3889.98% from $362000.0 recorded in Q2 2025.
  • Serina Therapeutics' Operating Leases' 5-year high stood at $675000.0 during Q4 2023, with a 5-year trough of $311000.0 in Q3 2025.
  • Its 3-year average for Operating Leases is $438000.0, with a median of $412500.0 in 2024.
  • Examining YoY changes over the last 5 years, Serina Therapeutics' Operating Leases showed a top increase of 0.0% in 2025 and a maximum decrease of 3889.98% in 2025.
  • Over the past 3 years, Serina Therapeutics' Operating Leases (Quarter) stood at $675000.0 in 2023, then crashed by 31.85% to $460000.0 in 2024, then crashed by 32.39% to $311000.0 in 2025.
  • Its last three reported values are $311000.0 in Q3 2025, $362000.0 for Q2 2025, and $412000.0 during Q1 2025.